Technical groundwork for early-stage biotech
Biotech teams need assays that hold up, a target profile partners can check, an evidence base reviewers can trace and a funding case grounded in science. We prepare that work, virtually and worldwide.
What we do
What we prepare for biosciences teams
Each item links to a service page with deliverables, inputs and boundaries. We prepare technical evidence, plans and strategy. We do not certify products, approve submissions or give legal opinions.
Assay development
Decide what to measure and how. We plan HPLC, LC-MS and ELISA methods, qualification and validation against ICH Q2(R2), and trace sources of run-to-run variation.
Assay developmentTarget product profile
Turn a scientific idea into minimum and target attributes, each mapped to a test method, with go/no-go criteria your team and partners can check.
Target product profileSystematic reviews
Protocol-led reviews reported to PRISMA 2020, with risk-of-bias appraisal and GRADE where pooled evidence allows. Rapid reviews state their shortcuts.
Systematic reviewsFormulation feasibility
Feasibility work for hydrogels, topical systems and sustained-release concepts: solubility, stability, excipient choice and stability-study design.
Formulation developmentCompetitive intelligence
Technology landscapes by mechanism, pipeline and trial-registry tracking, and monthly literature digests that a scientist verifies.
Competitive intelligenceGrant writing
Technical and commercialization sections for innovation funding applications such as SBIR/STTR and Horizon Europe, plus reviewer-style critique.
Grant writingAlso relevant: patent landscape analysis (technical analysis for your patent counsel, not a legal opinion) and biocompatibility evaluation for products that contact the body.
Illustrative situations
Problems we are typically asked to solve
These describe typical client types and problems. They are not client results, and we cannot promise outcomes, approvals or timelines.
ELISA results differ between runs
Biotech start-up. An ELISA gives different results from run to run, and a partner has questioned the data package.
How we advise. We review reagents, plate handling, controls and analysis, then propose a qualification plan with acceptance criteria.
You receive. A written assessment of likely variation sources and a method qualification plan.
A one-page definition of success for investors
Drug-delivery start-up. The team must explain to investors and partners what the product has to achieve, and today the answer lives in several documents.
How we advise. We draft a target product profile with minimum and target columns, map each attribute to a test method and propose go/no-go criteria.
You receive. A target product profile, a method map and a list of open data gaps.
A funding application with a weak technical section
Small biotech company. A draft innovation-funding application reads as a list of activities, with unclear work packages, milestones and risks.
How we advise. We read the draft as a reviewer would, then tighten work packages and milestones and rewrite the technical and commercialization sections.
You receive. An annotated critique and revised sections. Funding decisions remain with the funder.
Describe your biosciences project
Send a general description of the problem and your deadline. A scientist follows up by email and prepares a written quote once the scope is clear.